Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.81 |
| ▸ | MEN1 | O00255 | 5/20 | 0.81 |
| ▸ | RAB9A | P51151 | 5/20 | 0.81 |
| ▸ | NPC1 | O15118 | 4/20 | 0.81 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.78 |
| ▸ | CA12 | O43570 | 1/20 | 0.72 |
| ▸ | CA1 | P00915 | 1/20 | 0.72 |
| ▸ | CA2 | P00918 | 1/20 | 0.72 |
| ▸ | CA9 | Q16790 | 1/20 | 0.72 |
| ▸ | CASP3 | P42574 | 1/20 | 0.68 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4920497 | 0.96 | MAPT (0.75) | MAPTKMT2ASMN1; SMN2MEN1RAB9A | |
| SCHEMBL4111778 | 0.94 | TRPV1 (0.74) | MAPTKMT2ASMN1; SMN2MEN1RAB9A | |
| SCHEMBL4113506 | 0.93 | RAB9A (0.79) | MAPTKMT2ASMN1; SMN2MEN1RAB9A | |
| SCHEMBL4106971 | 0.92 | MAPT (0.73) | MAPTKMT2ASMN1; SMN2MEN1RAB9A | |
| SCHEMBL4112128 | 0.92 | MAPT (0.77) | MAPTKMT2ASMN1; SMN2MEN1RAB9A | |
| SCHEMBL4113529 | 0.91 | RAB9A (0.72) | MAPTKMT2ASMN1; SMN2MEN1RAB9A | |
| SCHEMBL4106965 | 0.91 | TRPV1 (0.77) | MAPTKMT2ASMN1; SMN2MEN1RAB9A | |
| SCHEMBL4118188 | 0.91 | MAPT (0.75) | MAPTKMT2ASMN1; SMN2MEN1RAB9A | |
| SCHEMBL4110239 | 0.90 | TRPV1 (0.76) | MAPTKMT2ASMN1; SMN2MEN1RAB9A | |
| SCHEMBL4128090 | 0.89 | MAPT (1.00) | MAPTKMT2ASMN1; SMN2MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | claimed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | claimed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1786422-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | Prosidion Limited (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006018662-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | PROSIDION LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | MAPT 1654/4885KMT2A 2807/4885SMN1; SMN2 4056/4885 |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MAPT 4151/4885KMT2A 1905/4885SMN1; SMN2 3931/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MAPT 4151/4885KMT2A 1905/4885SMN1; SMN2 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.